Adagio Therapeutics, Inc. (ADGI) Financial Statements (2024 and earlier)

Company Profile

Business Address 1601 TRAPELO ROAD
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments92,076,000542,224,000
Cash and cash equivalents92,076,000542,224,000
Receivables377,000 
Prepaid expense2,392,0003,190,000
Other current assets  1,521,000
Other undisclosed current assets282,072,00069,776,000
Total current assets:376,917,000616,711,000
Noncurrent Assets
Operating lease, right-of-use asset3,777,000 
Property, plant and equipment2,282,00083,000
Other noncurrent assets191,0003,297,000
Total noncurrent assets:6,250,0003,380,000
TOTAL ASSETS:383,167,000620,091,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23,428,00062,060,000
Accounts payable1,517,0005,783,000
Accrued liabilities21,911,00056,277,000
Other liabilities44,000 
Other undisclosed current liabilities1,559,000 
Total current liabilities:25,031,00062,060,000
Noncurrent Liabilities
Liabilities, other than long-term debt2,165,0006,000
Other liabilities 6,000
Operating lease, liability2,165,000 
Other undisclosed noncurrent liabilities 1,0006,000
Total noncurrent liabilities:2,166,00012,000
Total liabilities:27,197,00062,072,000
Equity
Equity, attributable to parent355,970,000558,019,000
Common stock11,00011,000
Additional paid in capital889,657,000850,125,000
Accumulated other comprehensive loss(272,000)(8,000)
Accumulated deficit(533,426,000)(292,109,000)
Total equity:355,970,000558,019,000
TOTAL LIABILITIES AND EQUITY:383,167,000620,091,000

Income Statement (P&L) (USD)

12/31/2023
12/31/2022
12/31/2021
Operating expenses(248,031,000)(226,908,000)
Operating loss:(248,031,000)(226,908,000)
Nonoperating income
(Investment Income, Nonoperating)
6,714,000118,000
Loss from continuing operations:(241,317,000)(226,790,000)
Loss before gain (loss) on sale of properties:(226,790,000)
Net loss available to common stockholders, diluted:(241,317,000)(226,790,000)

Comprehensive Income (USD)

12/31/2023
12/31/2022
12/31/2021
Net loss:(241,317,000)(226,790,000)
Comprehensive loss:(241,317,000)(226,790,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(264,000)(8,000)
Comprehensive loss, net of tax, attributable to parent:(241,581,000)(226,798,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: